Rheumatology News

Most new organ damage in systemic lupus erythematosus occurs in the first year after diagnosis, with the greatest impacts reported in the cardiovascular and musculoskeletal systems, according to data published in Lupus Science & Medicine.

The American College of Rheumatology has submitted comments to CMS on proposed cuts to physician payments, warning of worsened burnout and staff shortages, and calling for “appropriate reimbursement,” according to a press release.

Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.

The implementation of treat-to-target approaches for rheumatoid arthritis remains largely suboptimal, but could be improved with telehealth and other measures, according to data published in Arthritis Care & Research.

Radiotherapy poses no significant risks for worsening disease in patients with systemic sclerosis, but entails “variable risk” for both acute and late toxicities, according to data published in The Journal of Rheumatology.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.

Practicing shared decision-making increases overall trust in health care providers among patients with systemic lupus erythematosus, according to data published in Arthritis Care & Research.

COVID-19 does not increase patients’ risk for developing myalgic encephalomyelitis/chronic fatigue syndrome during the 1-year period post infection, according to a registry study published in JAMA Network Open.

The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.